EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Phase II Evaluation of Ultra-Hypofractionated Postoperative Radiation Therapy for Breast Cancer: Toxicity and Efficacy in a Single-Center Nonrandomized Prospective Study

Marcel Fang iD, Vinicius de Carvalho Gico iD, Lucas Casimiro, Bruno Takatsu iD, Elson Santos Neto iD, Rossana Veronica Mendoza Lopez, Gustavo Vilela Costa Pinto, Gustavo Nader Marta iD

JCO Global Oncology · 2025

DOI: 10.1200/go-24-00277 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Marcel Fang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Oncology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil. Hauptthemen laut MEDLINE: Breast Neoplasms, Radiation Dose Hypofractionation. Die Arbeit nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To evaluate the toxicity profile and efficacy of postoperative ultra-hypofractionated radiation therapy in elderly patients with breast cancer. MATERIALS AND METHODS This is a nonrandomized, single-center, prospective Phase II trial. Patients with breast cancer older than 65 years were treated with ultra-hypofractionated radiation therapy in 5 fractions of 5.7 Gy on alternate days in the breast or chest wall, or regional lymph nodes. The primary end point was acute toxicity. RESULTS A total of 60 patients were analyzed, with a median follow-up of 42.5 months (range, 13.8-66.2). Most patients presented pathologic stage I (56.6%, n = 34) or stage II (33.3%, n = 20) disease. Regional lymph node irradiation was performed in 22% (n = 13) of patients. During treatment, 51% (n = 31) of patients experienced grade 1 or 2 acute toxicity, with no cases of grade 3 acute toxicity reported. Late toxicity included 1.7% (n = 1) of patients developing grade 3 fibrosis and 1.7% (n = 1) developing grade 3 pneumonitis. Regional lymph node irradiation was not associated with a statistically significant increase in toxicity risk ( P = .194). Cosmesis evaluations revealed no significant changes when comparing pretreatment assessments with evaluations at 10 weeks ( P = .223) and 26 weeks ( P = .615) post-treatment. Quality of life was not adversely affected, regardless of whether regional lymph nodes were irradiated. Recurrence rates included two patients with both locoregional and distant recurrence and five patients with distant recurrence. The 3-year disease-free survival probability was 81.7%, and the 3-year overall survival probability was 86.7%. CONCLUSION This study demonstrates the safety of ultra-hypofractionated radiation therapy in terms of toxicity in patients with breast cancer. The findings for side effects, cosmesis, quality of life, and survival outcomes are consistent with those observed in moderately hypofractionated radiation therapy regimens, suggesting its use as a viable treatment option in this demographic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsRadiation Dose HypofractionationHumansFemaleAgedProspective StudiesAged, 80 and overTreatment OutcomeRadiotherapy, Adjuvant

Autor:innen und Institutionen

  • Department of Radiology and Oncology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil.
  • Instituto de Pesquisa Prevent Senior, Sao Paulo, Brazil.
  • Sharett Institute of Oncology, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Instituto do Câncer do Estado de São Paulo (ICESP), Universidade de São Paulo, Sao Paulo, Brazil.
  • Centro de Referência da Saúde da Mulher, Sao Paulo, Brazil.
  • Faculdade de Ciências Médicas de Santos, São Paulo, Brazil.

ORCID-Profile: Marcel Fang, Vinicius de Carvalho Gico, Bruno Takatsu, Elson Santos Neto, Gustavo Nader Marta

Zitieren

APA

Fang, M., Gico, V. C., Casimiro, L., Takatsu, B., Santos Neto, E., Mendoza Lopez, R. V., Costa Pinto, G. V., & Marta, G. N. (2025). Phase II Evaluation of Ultra-Hypofractionated Postoperative Radiation Therapy for Breast Cancer: Toxicity and Efficacy in a Single-Center Nonrandomized Prospective Study. JCO Global Oncology. https://doi.org/10.1200/go-24-00277

Vancouver

Fang M, Gico VC, Casimiro L, Takatsu B, Santos Neto E, Mendoza Lopez RV, et al. Phase II Evaluation of Ultra-Hypofractionated Postoperative Radiation Therapy for Breast Cancer: Toxicity and Efficacy in a Single-Center Nonrandomized Prospective Study. JCO Global Oncology. 2025. doi:10.1200/go-24-00277

BibTeX
@article{Fang2025,
  author = {Fang, Marcel and Gico, Vinicius de Carvalho and Casimiro, Lucas and Takatsu, Bruno and Santos Neto, Elson and Mendoza Lopez, Rossana Veronica and Costa Pinto, Gustavo Vilela and Marta, Gustavo Nader},
  title = {Phase II Evaluation of Ultra-Hypofractionated Postoperative Radiation Therapy for Breast Cancer: Toxicity and Efficacy in a Single-Center Nonrandomized Prospective Study},
  journal = {JCO Global Oncology},
  year = {2025},
  doi = {10.1200/go-24-00277}
}
Kostenlos starten →